These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 33216972)

  • 1. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCMA-targeted immunotherapy for multiple myeloma.
    Yu B; Jiang T; Liu D
    J Hematol Oncol; 2020 Sep; 13(1):125. PubMed ID: 32943087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BCMA in Multiple Myeloma.
    Tan CR; Shah UA
    Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody treatment in multiple myeloma.
    Maples KT; Johnson C; Lonial S
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):166-174. PubMed ID: 33739965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
    Martino M; Paviglianiti A
    Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
    [No Abstract]   [Full Text] [Related]  

  • 10. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 11. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.
    Abramson HN
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCMA-targeting approaches for treatment of multiple myeloma.
    Chen Y; Nagarajan C; Tan MS; Martinelli G; Cerchione C
    Panminerva Med; 2021 Mar; 63(1):28-36. PubMed ID: 32955181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rethinking mechanisms of neurotoxicity with BCMA directed therapy.
    Mohyuddin GR; Banerjee R; Alam Z; Berger KE; Chakraborty R
    Crit Rev Oncol Hematol; 2021 Oct; 166():103453. PubMed ID: 34461271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
    Su CT; Ye JC
    J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
    De Novellis D; Fontana R; Giudice V; Serio B; Selleri C
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
    Reyes KR; Liu YC; Huang CY; Banerjee R; Martin T; Wong SW; Wolf JL; Arora S; Shah N; Chari A; Chung A
    Blood Adv; 2024 May; 8(9):2207-2216. PubMed ID: 38429087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
    Martino M; Gamberi B; Antonioli E; Aquino S; Della Pepa R; Malerba L; Mangiacavalli S; Pezzatti S; Bringhen S; Zamagni E
    Expert Rev Hematol; 2024 Jul; 17(7):375-390. PubMed ID: 38770902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.